
anusorn nakdee
Biohaven (BHVN) shares rose on Thursday after the company announced early-stage trial data for its cancer candidate BHV-1530 and disclosed its plans to advance the antibody-drug conjugate in a pivotal trial as early as next year.
Based on an Oct. 19
